Compared to the extensive biological evaluation of hydroxamate-based HDACi, there has been limited investigation into the pharmacokinetics (PK), pharmacodynamics (PD), and pharmacological effects of mercaptoacetamide-based HDAC6 inhibitors in cancer and Alzheimer’s disease models. The gene discussed is HDAC6; the disease is Alzheimer disease.